Stem cell trial shows promise for type 2 diabetes

11/9/2011 | Australian Life Scientist

Mesoblast's mesenchymal precursor cells helped maintain lower fasting glucose levels in nonhuman primates with type 2 diabetes over eight weeks, the company announced. MPC-treated primates also had significant reductions in circulating C-reactive protein, a sign of cardiovascular disease risk, experts said.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA